Success examples
Systematic Application of a Cellular Thermal Shift Assay for Inferring Inhibitor Binding Affinity to 17βHSD13 in a Humanized Liver Homogenate

Lunnerdal S., Wågberg F., Dahl G., Ahnmark A., Hansson P., Sampers E., Madeyski-Bengtson K., Lee W., Löfgren L., Zarrouki B., Hallén S., Lundbäck T. 

Biochemistry. 2026, 65(3):311-324.

HSD17B13 inhibitor
DOI
PubMed
Success examples
Structural Studies of Fourth-Generation EGFR Inhibitors Reveal Insights into Selective T790M and C797S Targeting

Damghani T., Song S., Lin K. S., Li J., Heppner D. E.

ACS Medicinal Chemistry Letters 2026.

4th gen EGFR inhibitor
DOI
Success examples
Mixed Lineage Kinase Domain-Like Protein (MLKL): From Mechanisms to Therapeutic Opportunities

Xu L., Zhuang C.

Adv Sci (Weinh). 2025, 12(35):e09277.

MLKL inhibitor
DOI
PubMed
Success examples
Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer models

Slavic Obradovic K., Ebner F., Artemov A. V., Miotto M., Traexler P-E., Jacob R., Thanh H. P. T., Ruzicka R., Wernitznig A., Baumann I., Gerlach D., Impagnatiello M-A., Siena S., Murphy M., House R., Reiser U., Santoro V., Popow J., Carotta S., Baum A., Lipp J., Bardelli A., Tontsch-Grunt U., Russo M., Aichinger M.

Cell Rep Med. 2025, 6(9):102313.

Orally bioavailable BET inhibitor
DOI
PubMed
Success examples
A Gold-PROTAC Degrades the Oncogenic Tyrosine Kinase MERTK: Insights into the Degradome from a Steady-State System

Thomas S. R., Iellici T., Park M., Klaus E., Bileck A., Gerner C., Meier-Menches S. M., Casini A.

ACS Chem Biol. 2026, 21(1):170-186.

SMARCA2 PROTAC
DOI
PubMed
Success examples
FAK inhibition disrupts tumor growth, apoptosis, and transcriptional regulation in GI-NETs

Toffoli L., Ditsiou A., Triboli L., Hamm V., Moschioni E., D'Este F., Gagliano T.

Endocr Oncol. 2025, 5(1):e250052.

PTK2 PROTAC
DOI
PubMed